Drug Profile

CONV 01-alpha + PSMA I&T

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Convergent Therapeutics
Class Antineoplastics; Diagnostic agents; Drug conjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2025 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
28 Mar 2025 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in USA (Parenteral)
23 Oct 2022 Radiopharm Theranostics and NorthStar Medical Radioisotopes enters into a clinical supply agreement for the supplyof Radiopharm Theranostics with Actinium-225

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com